Home > Publications Database > Pain and agitation treatment in severe dementia patients: The need for Italian Mobilization–Observation–Behavior–Intensity–Dementia (I-MOBID2) pain scale translation, adaptation and validation with psychometric testing > print

001     164544
005     20240313115346.0
024 7 _ |a 10.1016/j.biopha.2022.113013
|2 doi
024 7 _ |a 0300-0893
|2 ISSN
024 7 _ |a 0753-3322
|2 ISSN
024 7 _ |a 1950-6007
|2 ISSN
024 7 _ |a altmetric:129999536
|2 altmetric
024 7 _ |a pmid:35658247
|2 pmid
037 _ _ |a DZNE-2022-01093
082 _ _ |a 610
100 1 _ |a Scuteri, D.
|b 0
245 _ _ |a Pain and agitation treatment in severe dementia patients: The need for Italian Mobilization–Observation–Behavior–Intensity–Dementia (I-MOBID2) pain scale translation, adaptation and validation with psychometric testing
260 _ _ |a Paris [u.a.]
|c 2022
|b Elsevier
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1655112456_6958
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a ISSN 0753-3322 not unique: **2 hits**.(CC BY-NC-ND 4.0)
520 _ _ |a The 97% of dementia patients develops fluctuant neuropsychiatric symptoms often related to under-diagnosed and unrelieved pain. Up to 80% severe demented nursing home residents experiences chronic pain due to age-related comorbidities. Patients lacking self-report skills risk not to be appropriately treated for pain. Mobilization–Observation–Behavior–Intensity–Dementia (MOBID2) is the sole pain scale to consider the frequent co-occurrence of musculoskeletal and visceral pain and to unravel concealed pain through active guided movements. Accordingly, the Italian real-world setting can benefit from its translation and validation. This clinical study provides a translated, adapted and validated version of the MOBID2, the Italian I-MOBID2. The translation, adaptation and validation of the scale for non-verbal, severe demented patients was conducted according to current guidelines in a cohort of 11 patients over 65 with mini-mental state examination ≤ 12. The I-MOBID2 proves: good face and scale content validity index (0.89); reliable internal consistency (Cronbach’s α = 0.751); good to excellent inter-rater (Intraclass correlation coefficient, and test-retest (ICC = 0.902) reliability. The construct validity is high (Rho = 0.748 p < 0.05 for 11 patients, Spearman rank order correlation of the overall pain intensity score with the maximum item score of I-MOBID2 Part 1; rho=0.895 p < 0.01 for 11 patients, for the overall pain intensity score with the maximum item score of I-MOBID2 Part 2) and a good rate of inter-rater and test-retest agreement was demonstrated by Cohen’s K = 0.744. The average execution time is of 5.8 min, thus making I-MOBID2 a useful tool suitable also for future development in community setting with administration by caregivers.
536 _ _ |a 351 - Brain Function (POF4-351)
|0 G:(DE-HGF)POF4-351
|c POF4-351
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, Journals: pub.dzne.de
650 _ 2 |a Chronic Pain: psychology
|2 MeSH
650 _ 2 |a Dementia: therapy
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Pain Measurement
|2 MeSH
650 _ 2 |a Psychometrics
|2 MeSH
650 _ 2 |a Reproducibility of Results
|2 MeSH
650 _ 2 |a Surveys and Questionnaires
|2 MeSH
700 1 _ |a Contrada, M.
|b 1
700 1 _ |a Loria, T.
|b 2
700 1 _ |a Sturino, D.
|b 3
700 1 _ |a Cerasa, A.
|b 4
700 1 _ |a Tonin, P.
|b 5
700 1 _ |a Sandrini, G.
|b 6
700 1 _ |a Tamburin, S.
|b 7
700 1 _ |a Bruni, A. C.
|b 8
700 1 _ |a Nicotera, P.
|0 P:(DE-2719)2010732
|b 9
|u dzne
700 1 _ |a Corasaniti, M. T.
|b 10
700 1 _ |a Bagetta, G.
|b 11
773 _ _ |a 10.1016/j.biopha.2022.113013
|g Vol. 150, p. 113013 -
|0 PERI:(DE-600)392415-4
|p 113013
|t Biomedicine & pharmacotherapy
|v 150
|y 2022
|x 0300-0893
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/164544/files/DZNE-2022-01093.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/164544/files/DZNE-2022-01093.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:164544
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 9
|6 P:(DE-2719)2010732
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-351
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Brain Function
|x 0
914 1 _ |y 2022
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
|0 LIC:(DE-HGF)CCBYNCND4
|2 HGFVOC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b BIOMED PHARMACOTHER : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
920 1 _ |0 I:(DE-2719)1030000
|k Scientific board
|l Scientific board
|x 0
920 1 _ |0 I:(DE-2719)1013003
|k AG Bano
|l Aging and neurodegeneration
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1030000
980 _ _ |a I:(DE-2719)1013003
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21